In search of the optimal management strategy for non ‐alcoholic fatty liver disease in type 2 diabetes
AbstractNon ‐alcoholic fatty liver disease (NAFLD) is present in over two‐thirds of individuals with type 2 diabetes. Diabetes increases the risk of NAFLD progression, especially the development of non‐alcoholic steatohepatitis (NASH), advanced fibrosis (AF; defined as fibrosis stage ≥3), and hepatocell ular carcinoma (HCC) (1). On the other hand, NAFLD also puts patients at a higher risk of cardiovascular diseases (CVD) (2). Driven by the rising prevalence of both obesity and type 2 diabetes, and increasing life‐expectancy of patients with type 2 diabetes consequent to the improved standard of c are, it is envisioned that NAFLD will soon become a major diabetic complication.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Chi ‐Ho Lee,
David Tak‐Wai Lui,
Karen Siu‐Ling Lam Tags: JDI UPDATES Source Type: research
More News: Alcoholism | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Heart | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology